Overview
Indications
Clinical Studies (14) [see]. AMPYRA is indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed
Contraindications
When this intervention should not be used
The use of AMPYRA is contraindicated in the following conditions: Warnings and Precautions (5.1) see] History of seizure [ Warnings and Precautions (5.2) Moderate or severe renal impairment (CrCl≤50 mL/min) [see] Warnings and Precautions (5.4) History of hypersensitivity to AMPYRA or 4-aminopyridine
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
7 trials linked to this intervention
Recent Trials
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.
FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra
Resistance Training and Amino Pyridine in Multiple Sclerosis
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Fampridine (substance)
- SNOMED CT
- 80994002
- UMLS CUI
- C0000477
- RxNorm CUI
- 897018
- Labeler
- Merz Pharmaceuticals, LLC
Clinical Data
This intervention maps to 6 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.